跳至主要内容
临床试验/ITMCTR2000003279
ITMCTR2000003279尚未招募1 期

A randomized, double-blind, placebo, parallel controlled trial for Pien-Tze-Huang Capsules in treating convalescent novel coronavirus pneumonia (COVID-19) patient with SARS-CoV-2 positive.

Hubei Provincial Hospital of TCM0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 70(—)
性别
All

入选标准

  • (1) Patients who meet the COVID-19 diagnostic criteria and discharge standards, but the later SARS-CoV-2 virus nucleic acid test is positive;
  • (2) Aged 18 to 70 years old;
  • (3) Signed informed consent.

排除标准

  • 1. Accompanied by severe basic diseases affecting survival, including uncontrolled clinically significant heart, kidney, digestive, blood diseases, neuropsychiatric diseases, immune diseases, metabolic diseases, malignant tumors, severe malnutrition, etc.;
  • 2. Unstable angina pectoris or myocardial infarction in the last 1 month;
  • 3. Allergic constitution, allergic to the drug ingredients involved in the treatment program;
  • 4. Pregnant or nursing women;
  • 5. Mental state cannot cooperate, suffer from mental illness, have no self-control, cannot express clearly;
  • 6. Participating in other clinical trials;
  • 7. According to the judgment of the researchers, patients who will be included in the group will have complications or poor compliance, which will affect the efficacy and safety evaluation.

研究者

发起方
Hubei Provincial Hospital of TCM

相似试验